Michel Garneau

2.0k total citations
57 papers, 1.3k citations indexed

About

Michel Garneau is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Michel Garneau has authored 57 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hepatology, 19 papers in Infectious Diseases and 17 papers in Epidemiology. Recurrent topics in Michel Garneau's work include Hepatitis C virus research (21 papers), HIV/AIDS drug development and treatment (19 papers) and Metabolism and Genetic Disorders (8 papers). Michel Garneau is often cited by papers focused on Hepatitis C virus research (21 papers), HIV/AIDS drug development and treatment (19 papers) and Metabolism and Genetic Disorders (8 papers). Michel Garneau collaborates with scholars based in Canada, Germany and Egypt. Michel Garneau's co-authors include Henri Brunengraber, Florian David, Christine Des Rosiers, Jianmin Duan, Jane Montgomery, Gordon T. Bolger, Montse Llinàs‐Brunet, George Kukolj, Pierre L. Beaulieu and Michael G. Cordingley and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Analytical Biochemistry.

In The Last Decade

Michel Garneau

54 papers receiving 1.3k citations

Peers

Countries citing papers authored by Michel Garneau

Since Specialization

Citations

This map shows the geographic impact of Michel Garneau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Garneau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Garneau more than expected).

Fields of papers citing papers by Michel Garneau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Garneau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Garneau. The network helps show where Michel Garneau may publish in the future.

Co-authorship network of co-authors of Michel Garneau

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Garneau. A scholar is included among the top collaborators of Michel Garneau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Garneau. Michel Garneau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of tetrahydroindazoles as a novel class of potent and in vivo efficacious gamma secretase modulators 2018 ·Bioorganic & Medicinal Chemistry ·Kai Gerlach, Scott Hobson, Christian Eickmeier, (unknown), (unknown), Peter Sieger, Michel Garneau, S. Hoerer, N. Heine	10
2	Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity 2015 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu, Gordon T. Bolger, (unknown), Martin Duplessis, Gulrez Fazal, Alexandre Gagnon, Michel Garneau, (unknown), Timothy A. Stammers, George Kukolj, Jianmin Duan	5
3	A prodrug strategy for the oral delivery of a poorly soluble HCV NS5B thumb pocket 1 polymerase inhibitor using self-emulsifying drug delivery systems (SEDDS) 2014 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu, (unknown), Michel Garneau, Laibin Luo, Timothy A. Stammers, (unknown), Dominik Wernic, George Kukolj, Jianmin Duan	13
4	Aza follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 1: Mitigating the genotoxic liability of an aniline metabolite 2014 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu, Gordon T. Bolger, Martin Duplessis, Alexandre Gagnon, Michel Garneau, Timothy A. Stammers, George Kukolj, Jianmin Duan	7
5	A strategy to reduce biliary clearance in early drug discovery 2013 ·Journal of Pharmacological and Toxicological Methods ·Nathalie Rioux, (unknown), (unknown), (unknown), Michel Garneau, Maria Ribadeneira, Jianmin Duan	1
6	Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay 2013 ·Bioorganic & Medicinal Chemistry Letters ·Timothy A. Stammers, René Coulombe, Martin Duplessis, Gulrez Fazal, Alexandre Gagnon, Michel Garneau, Sylvie Goulet, Araz Jakalian, Steven R. LaPlante, Jean Rancourt, Bounkham Thavonekham, Dominik Wernic, George Kukolj, Pierre L. Beaulieu	15
7	Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: Discovery of potent succinamide inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Murray D. Bailey, Josée Bordeleau, Michel Garneau, Mélissa Leblanc, Christopher T. Lemke, Jeff A. O’Meara, Peter W. White, Montse Llinàs‐Brunet	0
8	Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-Arylproline analogs 2013 ·Bioorganic & Medicinal Chemistry Letters ·François Bilodeau, Murray D. Bailey, (unknown), Josée Bordeleau, Pat Forgione, Michel Garneau, Élise Ghiro, Vida Gorys, Ted Halmos, (unknown), Mélissa Leblanc, Christopher T. Lemke, Julie Naud, Jeff A. O’Meara, Peter W. White, Montse Llinàs‐Brunet	4
9	Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions 2012 ·Pharmaceutical Research ·Alexander Sedykh, Denis Fourches, Jianmin Duan, Oliver Hucke, Michel Garneau, Hao Zhu, Pierre Bonneau, Alexander Tropsha	68
10	Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor 2011 ·Xenobiotica ·Jianmin Duan, Chan‐Loi Yong, Michel Garneau, Ma’an Amad, Gordon T. Bolger, (unknown), (unknown), (unknown), Martin Jutras, (unknown), Peter W. White, Montse Llinàs‐Brunet, Richard C. Bethell, Michael G. Cordingley	13
11	From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: Indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons 2011 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu, James Gillard, (unknown), Jianmin Duan, Michel Garneau, George Kukolj, Marc‐André Poupart	18
12	N-Acetamideindolecarboxylic acid allosteric ‘finger-loop’ inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies 2010 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu, (unknown), James Gillard, Christian Brochu, René Coulombe, Nathalie Dansereau, Jianmin Duan, Michel Garneau, Araz Jakalian, Peter Kühn, Lisette Lagacé, Steven R. LaPlante, Ginette McKercher, (unknown), Martin Poirier, Marc‐André Poupart, Timothy A. Stammers, Louise Thauvette, Bounkham Thavonekham, George Kukolj	12
13	Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: Improved drug-like properties through C-2 SAR in three sub-series 2010 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu, Nathalie Dansereau, Jianmin Duan, Michel Garneau, James Gillard, Ginette McKercher, Steven R. LaPlante, (unknown), Louise Thauvette, George Kukolj	8
14	Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase 2004 ·Antiviral Research ·Michel Liuzzi, (unknown), (unknown), (unknown), Gordon T. Bolger, Michel Garneau, (unknown), (unknown), (unknown), Bruno Simoneau	29
15	Acute murine cytomegalovirus infection: a model for determining antiviral activity against CMV induced hepatitis 1999 ·Antiviral Research ·Gordon T. Bolger, (unknown), (unknown), (unknown), (unknown), Michel Garneau, Michael G. Cordingley	7
16	The use of electroretinography to study MCMV induced retinitis in the SCID mouse 1998 ·Antiviral Research ·Michel Garneau, Gordon T. Bolger, (unknown), (unknown), Michael G. Cordingley	2
17	A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo 1994 ·Nature ·Michel Liuzzi, Robert Déziel, (unknown), Pierre L. Beaulieu, Anne-Marie Bonneau, (unknown), James G. Chafouleas, Michel Garneau, Jorge Jaramillo, Richard L. Krogsrud, Lisette Lagacé, (unknown), (unknown), Yvan Guindon	109
18	Cardiac responses and binding sites for endothelin in normal and cardiomyopathic hamsters. 1992 ·Journal of Pharmacology and Experimental Therapeutics ·Gordon T. Bolger, R. Stephen Berry, Francine Liard, Michel Garneau, Jorge Jaramillo	3
19	Pseudoketogenesis in the perfused rat heart. 1988 ·Journal of Biological Chemistry ·Gregor Fink, (unknown), Christine Des Rosiers, Michel Garneau, Florian David, (unknown), Bernard R. Landau, Henri Brunengraber	40
20	Ketogenesis in muscle: artifact or reality 1986 ·Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States) ·(unknown), (unknown), Michel Garneau, Florian David, Bernard R. Landau, Henri Brunengraber	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact